Profil Penggunaan Obat pada Pasien COVID-19 di Rumah Sakit Umum Daerah Ulin Banjarmasin
DOI:
https://doi.org/10.20527/jps.v8i2.11144Keywords:
Novel Coronavirus disease 2019 (Covid-19)Abstract
Coronavirus disease 2019 (COVID-19) yang disebabkan oleh Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2) adalah infeksi virus baru yang pertama kali dilaporkan di Kota Wuhan, Tiongkok Tengah. Penyebaran virus ini semakin meningkat dan telah menyebar hampir ke seluruh Negara di dunia sehingga World Health Organization (WHO) mengumumkannya sebagai pandemi. Hingga saat ini, masih belum ditemukan obat antivirus khusus untuk penyakit ini dan penatalaksanaannya masih berupa terapi simptomatik dan suportif. Penelitian ini bertujuan untuk menganalisa profil penggunaan obat pada pasien COVID-19 di Rumah Sakit Umum Daerah Ulin Banjarmasin. Penelitian non-eksperimental ini menggunakan metode purposive sampling dengan beberapa kriteria yaitu rekam medis pasien COVID-19 rawat inap dan tanpa komorbid, yang mana telah dilakukan secara retrospektif pada periode 1–31 Januari 2021. Dari 146 sampel, diperoleh 12 sampel yang sesuai dengan kriteria. Berdasarkan jenis kelamin, laki laki lebih banyak terinfeksi COVID-19 yaitu (58,33%). Berdasarkan usia, paling banyak terjadi pada rentang usia 31-40 tahun (41,67%). Hasil penelitian menunjukkan pasien mendominasi berada pada parameter gejala klinis kategori ringan (75%). Urutan terbanyak penggunaan obat adalah suplemen dan vitamin (49,35%), antibiotik (9,47%) dan antivirus (7,15%). Oleh karen itu, dapat disimpulkan bahwa jenis kelamin dan usia sangat mempengaruhi tingkat keparahan penyakit COVID-19 dan berpengaruh pada penggunaan obat untuk penyembuhan, gejala klinis yang paling banyak dijumpai adalah kategori ringan sehingga penggunaan obat terbanyak adalah golongan suplemen dan vitamin. Kata Kunci: Novel Coronavirus disease 2019 (COVID-19), Pola, Pengobatan  Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new viral infection that was first reported in Wuhan City, Central China. The spread of this virus is increasing and has spread to almost all countries in the world so that the World Health Organization (WHO) declared it a pandemic. Until now, there is still no specific antiviral drug for this disease and its management is still in the form of symptomatic and supportive therapy. This study aims to determine the profile of drug use in COVID-19 patients at the Banjarmasin Ulin Regional General Hospital. This non-experimental study used a purposive sampling method with several criteria, namely medical records of inpatients of COVID-19 patients and without comorbidities, which were carried out retrospectively in the period 1–31 January 2021. From 146 samples, 12 samples were obtained that matched the criteria. . Based on gender, men were more infected with COVID-19, namely (58.33%). Based on age, most occurred in the age range of 31-40 years (41.67%). Based on clinical symptoms more mild category (75%). The highest use of drugs is the first group of supplements and vitamins (49.35%), secondly, the antibiotic group (9.47%) and thirdly, the antiviral group (7.15%). Gender and age greatly affect the severity of COVID-19 disease and affect the use of drugs for healing, the most common clinical symptoms are in the mild category so that the most drug use is in the supplement and vitamin group.References
Aranow, C. (2011). Vitamin D and the Immune System. J Investig Med, 59(6),881–886. https://doi.org/10.231/JIM.0b013e318 21b8755
COVID-19 Treatment Guidelines Panel. (2020). COVID-19 Treatment Guidelines. https://www.cOVID19treatmentguidelines. nih.gov/
Drew & Asri C. Adisasmita.(2021). Gejala dan komorbid yang memengaruhi mortalitas pasien positif COVID-19 di Jakarta Timur, Maret-September 2020 Clement, Tarumanagara Medical Journal Vol. 3, No. 3, 274-283, April 2021 274
Fatmah. (2006). Respons Imunitas Yang Rendah Pada Tubuh Manusia Usia Lanjut, Makara, Kesehatan, Vol. 10, No. 1, Juni 2006: 47-53
Fisher, B. J., Seropian, I. M., Kraskauskas, D., Thakkar, J. N., Voelkel, N. F., Fowler, A. A., & Natarajan, R. (2011). Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Critical Care Medicine, 39(6), 1454–1460. https://doi.org/10.1097/CCM.0b013e3 182120cb8
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X. and Cheng, Z., (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China. The lancet, 395(10223), pp.497- 506. DOI: 10.1016/S0140-6736(20)30183-5
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 18e. New York, NY: McGraw-Hill. 2020.
Lu, H., Stratton, C.W. and Tang, Y.W., (2020). Outbreak of Pneumonia of Unknown Etiology in Wuhan China: The Mystery and the Miracle. Journal of Medical Virology. DOI: 10.1002/jmv.25678
Mackenzie, J.S., David W.S. (2020). COVID-19: a novel zoonotic disease caused by a coronavirus from china: what we know and what we don’t. Microbiology Australia
Menteri Kesehatan Republik Indonesia, (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/413/2020 tentang Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID- 19). Kementerian Kesehatan Republik Indonesia. Jakarta. Available at: https://kesmas.kemkes.go.id/perpu/konten/kmk/kmk_no._hk.01.07- menkes-413-2020_ttg_pedoman_pencegahan_dan_pengendalian_cOVID- 19
Metlay, J., Waterer G., (2020). Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Annals of Internal Medicine, 1-3, doi: 10.7326/M20-2189
Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: A meta-analysis. J Community Health. Dec 2020;45(6):1270- 82
PDPI, PERKI, PAPDI, PERDATIN, IDAI, 2020. Protokol Tatalaksana COVID-19, Edisi 2: Agustus 2020. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Jakarta. Available at: https://www.papdi.or.id/download/938-pedomantatalaksana-cOVID-19-edisi-2-agustus-2020
Satria R.M.A., Resty V.T., Dzajuli C. (2020). Analisis Faktor Risiko Kematian Dengan Penyakit Komorbid COVID-19. Jurnal Keperawatan Silampari DOI: https://doi.org/10.31539/jks.v4i1.1587
Setiadi, A.P. Yosi, I. W, Steven, V. H. Cecilia, B. Bobby, P. Eko,S. 2020. Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif. Jurnal Farmasi Klinik Indonesia. http://ijcp.or.id DOI: 10.15416/ijcp.2020.9.1.70
Wang, W., Tang, J. and Wei, F., 2020. Updated understanding of the outbreak of 2019 novel coronavirus (2019â€nCoV) in Wuhan, China. Journal of medical virology, 92(4), pp.441-447. DOI: 10.1002/jmv.25689
Wenham, C., Smith, J., & Morgan, R. (2020). COVID-19: the Gendered Impacts of the Outbreak. In The Lancet (Vol. 395, Issue 10227, pp. 846–848). https://doi.org/10.1016/S0140-6736(20)30526-2
World Health Organisation. (2020). Naming the Coronavirus disease (COVID-19) and the virus that causes it. Coronavirus disease 2019: Technical guidance. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus- 2019/technical-guidance/naming-the-coronavirus-disease-(cOVID-2019)- and-the-virus-that-causes-it
World Health Organisation. (2020). Infection Prevention and Control During Health Care When Novel Coronavirus (nCoV) Infection is Suspected, Interim Guidance. [serial on TheInternet]. Available at: https://www.who.int/publicationsdetail/infection-preventionand-control-during-health-care-when-novelcoronavirus-(ncov)infection-is-suspected-20200125
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

.jpg)
